BOCA RATON, Fla.--(BUSINESS WIRE)--Jul. 31, 2018--
TherapeuticsMD, Inc. (NASDAQ:TXMD) today announced the launch of a $65
million underwritten public offering and a concurrent $20 million
registered direct offering to a strategic investor of shares of its
common stock. TherapeuticsMD also expects to grant the underwriters of
the underwritten public offering a 30-day option to purchase up to an
additional 15% of shares of common stock offered in the underwritten
public offering. All of the shares in the offerings are to be sold by
TherapeuticsMD. Both offerings are subject to market conditions, and the
closing of the registered direct offering is contingent upon the closing
of the underwritten offering, but the closing of the underwritten
offering is not contingent upon the closing of the registered direct
offering. There can be no assurance as to whether or when the offerings
may be completed, or as to the actual size or terms of the offerings.
Goldman Sachs & Co. LLC is acting as bookrunner for the underwritten
public offering. Cantor Fitzgerald & Co. is acting as joint bookrunning
manager for the underwritten public offering. The registered direct
offering is being made without an underwriter, placement agent, broker
TherapeuticsMD intends to use the proceeds of the offerings to fund a
portion of the costs for the commercial launch of its recently FDA
approved product, IMVEXXY™ (estradiol vaginal inserts) for the treatment
of moderate-to-severe dyspareunia (vaginal pain associated with sexual
activity), a symptom of vulvar and vaginal atrophy, due to menopause,
and to fund a portion of the costs for pre-commercialization and
commercialization activities for TX-001HR, its bio-identical hormone
therapy combination of 17-ßestradiol and progesterone in a single, oral
softgel drug candidate, for the treatment of moderate to severe
vasomotor symptoms due to menopause, and its one-year vaginal
contraceptive system candidate in-licensed from the Population Council.
TherapeuticsMD has filed shelf registration statements on Form S-3 with
the Securities and Exchange Commission (the “SEC”) with respect to the
offerings. Preliminary prospectus supplements and accompanying
prospectuses relating to the offerings will be filed with the SEC.
Before buying any shares of TherapeuticsMD’s common stock in the
underwritten public offering, you should carefully read the preliminary
prospectus supplement and the accompanying prospectus with respect to
such offering, together with the information incorporated by reference
therein. These documents contain important information that you should
consider when making your investment decision. TherapeuticsMD’s SEC
filings are available to the public from the SEC’s website at www.sec.gov.
When available, copies of the preliminary prospectus supplements and the
accompanying prospectuses relating to these offerings may also be
obtained by contacting Goldman Sachs & Co. LLC, Prospectus Department,
200 West Street, New York, NY 10282, telephone: 1-866-471-2526,
facsimile: 212-902-9316 or by emailing Prospectusemail@example.com;
or Cantor Fitzgerald & Co., Attention: Capital Markets, 499 Park Avenue,
6th Floor New York, New York 10022 or by emailing firstname.lastname@example.org.
This press release shall not constitute an offer to sell or the
solicitation of an offer to buy any securities, nor shall there be any
sale of these securities in any state or other jurisdiction in which
such offer, solicitation, or sale would be unlawful prior to the
registration or qualification under the securities laws of any such
state or other jurisdiction.
About TherapeuticsMD, Inc.
TherapeuticsMD, Inc. is an innovative healthcare company focused on
developing and commercializing novel products exclusively for women. Our
products are designed to address the unique changes and challenges women
experience through the various stages of their lives with a therapeutic
focus in family planning/ reproductive health and menopause management.
The company is committed to advancing the health of women and
championing awareness of their healthcare issues.
This press release by TherapeuticsMD, Inc. may contain
forward-looking statements. Forward-looking statements may include, but
are not limited to, statements relating to TherapeuticsMD’s objectives,
plans and strategies as well as statements, other than historical facts,
that address activities, events or developments that TherapeuticsMD
intends, expects, projects, believes or anticipates will or may occur in
the future. These statements are often characterized by terminology such
as “believes,” “hopes,” “may,” “anticipates,” “should,” “intends,”
“plans,” “will,” “expects,” “estimates,” “projects,” “positioned,”
“strategy” and similar expressions and are based on assumptions and
assessments made in light of management’s experience and perception of
historical trends, current conditions, expected future developments and
other factors believed to be appropriate. Forward-looking statements in
this press release are made as of the date of this press release, and
the company undertakes no duty to update or revise any such statements,
whether as a result of new information, future events or otherwise.
Forward-looking statements are not guarantees of future performance and
are subject to risks and uncertainties, many of which are outside of the
company’s control, that may cause actual results to differ materially,
including the risks and uncertainties associated with market conditions,
the satisfaction of customary closing conditions related to the
offerings, risks and uncertainties associated with TherapeuticsMD’s
business and finances in general and other risks described in the
sections titled “Risk Factors” in TherapeuticsMD’s filings with the SEC,
including its most recent Annual Report on Form 10-K, the preliminary
prospectus supplements with respect to the offerings and other filings
with the SEC.
View source version on businesswire.com: https://www.businesswire.com/news/home/20180731005933/en/
Source: TherapeuticsMD, Inc.
Nichol Ochsner, 561-961-1900 Ext. 2088
President, Investor Relations